Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes
- 1 May 2014
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 234 (1) , 146-151
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary interventionHeart, 2011
- 2011 Clinical Practice Guidelines for Type 2 Diabetes in KoreaDiabetes & Metabolism Journal, 2011
- Clinical determinants of aspirin resistance in diabetesDiabetes Research and Clinical Practice, 2010
- High on‐aspirin platelet reactivity as measured with aggregation‐based, cyclooxygenase‐1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic eventsJournal of Thrombosis and Haemostasis, 2010
- Aspirin Resistance in Healthy Drug-Naive Men Versus Women (from the Heredity and Phenotype Intervention Heart Study)The American Journal of Cardiology, 2009
- Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysisBMJ, 2008
- Prevalence and Clinical Characteristics of Aspirin Resistance in the Patients with Type 2 Diabetes MellitusKorean Diabetes Journal, 2008
- Prevalence of aspirin resistance in patients with type 2 diabetesActa Diabetologica, 2005
- Binding of Low Density Lipoprotein to Platelet Apolipoprotein E Receptor 2′ Results in Phosphorylation of p38MAPKJournal of Biological Chemistry, 2004
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002